Heart research hits plateau
Just in time for the American Heart Association’s annual meeting, Milwaukee Journal Sentinel reporter John Fauber offers something of a “state of the heart” address, explaining why, after years of breakthroughs and broad progress, cardiac research has suddenly hit a plateau. The short answer seems to be that, in a crowded market with a high bar for comparative effectiveness, companies can’t just pump out any old heart-related drug and get a guaranteed blockbuster anymore.
“Cardiology is no longer low-hanging fruit,” said James Stein, a cardiologist at the University of Wisconsin School of Medicine and Public Health. “I don’t see anything in the next five years that is going to dramatically change how we treat, other than the new blood thinners.”
Fauber pegs drugs that target genetic variation as the sector’s next growth area, but it looks like those won’t hit the market for another decade. At present, the only thing the industry can really hang its hat on is anticoagulants.
New CDC data pinpoint heart disease hot spots
Data from Medicare records of more than 28 million people each year between 2000 and 2006 in the 50 states, Washington, D.C., Puerto Rico and the U.S. Virgin Islands were used to create a county-level report on hospitalizations because of heart disease.
The CDC’s “Atlas of Heart Disease Hospitalizations Among Medicare Beneficiaries” shows that the highest hospitalization rates occur among blacks compared to other racial and ethnic groups and rates were highest in Appalachia, the Mississippi Delta, Texas and Oklahoma.
For more county-level health data, be sure to take a look at the County Health Rankings recently released by the Robert Wood Johnson Foundation and the University of Wisconsin.

